Both cytochrome CYP17
(P-450 17[alpha]-hydroxylase) and cytochrome CYP19 (P-450 aromatase) are involved in estrogen biosynthesis.
Abirateron asetat (AA) bir CYP17
inhibitorudur (17a-hidrolaz ve 17, 20-liyaz inhibisyonunun bir kombinasyonu).
Effects of individual polychlorinated naphthalene (PCN) components of Halowax 1051 and 2 defined, artificial PCN mixtures on AHR and CYP1A1 protein expression, steroid secretion and expression of enzymes involved in steroidogenesis (CYP17
, 17-HSD and CYP19) in porcine ovarian follicles.
Two Prevalent CYP17
Mutations and Genotype-Phenotype Correlations in 24 Brazilian Patients with 17-Hydroxylase Deficiency.
In 2017, Laekna struck its first deal with Novartis, acquiring global rights to develop a CYP17
inhibitor (CFG920), an oral androgen inhibitor, to treat prostate cancer.
Yonsa is a CYP17
inhibitor which uses proprietary SoluMatrix Fine Particle Technology to create a micronized (smaller particle size) formulation of abiraterone acetate tablets for the treatment of mCRPC in combination with methylprednisolone.
The conversion of pregnenolone to testosterone is achieved by a chain reaction of several enzymes, including 3[beta]-hydroxysteroid dehydrogenase (HSD3B1), 17[alpha]-hydroxylase (CYP17
), and 17[beta]- hydroxysteroid dehydrogenase (HSD17B) .
In the ?4-pathway in the ZF, cytochrome P-450 17 alpha-hydroxylase (CYP17
) catalyzes the conversion of pregnenolone and progesterone to 17a-hydroxypregnenolone and 17a-hydroxyprogesterone, respectively, so the levels of pregnenolone and 17a-hydroxyprogesterone do not vary significantly.
(1) One of these agents is abiraterone acetate (abiraterone), an orally available inhibitor of CYP17
that blocks adrenal and intra-tumoural androgen synthesis.
Association of CYP17
, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women.
we determine that Petitioner has shown by a preponderance of the evidence that all claims of the '438 patent for which trial was instituted, namely, claims 1-20, are unpatentable." The '438 patent describes administration of a therapeutically effective amount of a CYP17
inhibitor, such as abiraterone acetate, with a therapeutically effective amount of at least one additional therapeutic agent including, but not limited to, an anti-cancer agent, such as mitoxantrone, paclitaxel, docetaxel, leuprolide, goserelin, triptorelin, seocalcitol, bicalutamide, or flutamide, or a steroid, such as hydrocortisone, prednisone, or dexamethasone, the ruling states.
Bezerra de Castro et al., "Breast cancer risk and polymorphisms in genes involved in metabolism of estrogens (CYP17
, HSD17[beta]1, COMT and MnSOD): possible protective role of MnSOD gene polymorphism Val/Ala and Ala/Ala in women that never breast fed," Oncology Reports, vol.